- Home
- LBPH
as 11-21-2024 4:00pm EST
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 1.4B | IPO Year: | 2021 |
| Target Price: | $52.29 | AVG Volume (30 days): | 834.8K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.60 - $59.95 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Longboard Pharmaceuticals Inc. (LBPH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kaye Randall | LBPH | CMO | Oct 15 '24 | Sell | $59.04 | 16,667 | $983,936.35 | 17,920 | |
| Kaye Randall | LBPH | CMO | Sep 16 '24 | Sell | $32.47 | 16,666 | $527,318.17 | 17,920 |
Latest Longboard Pharmaceuticals Inc. News
LBPH Breaking Stock News: Dive into LBPH Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
9 days ago
Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment
Business Wire
10 days ago
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Business Wire
15 days ago
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
MT Newswires
a month ago
HC Wainwright Downgrades Longboard Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $60 From $80
The Wall Street Journal
a month ago
Health Care Roundup: Market Talk
Zacks
a month ago
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
MT Newswires
a month ago
B. Riley Downgrades Longboard Pharmaceuticals to Neutral From Buy, Raises Price Target to $60 From $45
MT Newswires
a month ago
Baird Downgrades Longboard Pharmaceuticals to Neutral From Outperform, Price Target is $60
Compare LBPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LBPH Longboard Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.